Sansalvamide induces pancreatic cancer growth arrest through changes in the cell cycle

Keyphrases

• Pancreatic Cancer 100%
• Growth Arrest 100%
• Cancer Growth 100%
• Sansalvamide A 100%
• Western Blot Analysis 66%
• Cyclin-dependent Kinase 4 (CDK4) 66%
• Cyclin E 66%
• Cyclin D1 (CCND1) 66%
• Pancreatic Cancer Cells 66%
• Cyclin A 66%
• G1 Cell Cycle Arrest 66%
• Flow Cytometry 33%
• Cell-to-cell 33%
• Cell Proliferation 33%
• Anticancer Activity 33%
• Antiproliferative Activity 33%
• Patient Survival 33%
• Anticancer Therapy 33%
• Cancer Cell Growth 33%
• Cyclin-dependent Kinase 6 (CDK6) 33%
• Life Cycle Analysis 33%
• Cell Counting 33%
• Cyclic Peptide 33%
• Cyclin-dependent Kinase 2 (CDK2) 33%
• Thymidine Incorporation 33%
• G(0) 33%
• CD18 33%
• Human Pancreatic Cancer Cell Line 33%
• Marine Fungi 33%
• AsPC-1 33%
• Line Blot 33%

Biochemistry, Genetics and Molecular Biology

• Cancer Cell 100%
• Cell Cycle 100%
• Western Blot 66%
• P21 66%
• Cyclin E 66%
• Cyclin A 66%
• Cyclin D1 66%
• Depsipeptide 33%
• Anticancer 33%
• Cell Proliferation 33%
• down Regulation 33%
• Upregulation 33%
• Antineoplastic Activity 33%
• Cell Cycle Checkpoint 33%
• Cell Cycle Arrest 33%
• G1 Phase 33%
• Antiproliferative Activity 33%
• G1/S Transition 33%
• Cell-Cycle Analysis 33%
• Cell Growth 33%
• DNA Synthesis 33%
• CD18 33%
• Flow Cytometry 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Pancreas Cancer 100%
• Growth Disorder 100%
• Western Blot 40%
• Cyclin E 40%
• Cyclin D1 40%
• Cyclin A 40%
• Flow Cytometry 20%
• CD18 Antigen 20%
• Cyclodepsipeptide 20%
• Thymidine 20%